Miglustat
Based on 7 publication(s) in Google Scholar
Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.99%
- No. CAS: 72599-27-0
- Fòrmula: C10H21NO4
- Peso molecular:219.28
-
Almacenamiento:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product-like Compound Library
HY-L021L
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Immunology/Inflammation Compound Library
HY-L007
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Miglustat
More- Cell. 2019 Dec 12;179(7):1483-1498.e22. [Abstract]
- Nat Commun. 2024 Aug 14;15(1):6970. [Abstract]
- Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
- Front Pharmacol. 2023 Jun 26:14:1191692. [Abstract]
- J Virol. 2026 Apr 21;100(4):e0027026. [Abstract]
- J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
- Preprints. 2023 Dec 20.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
Cell Imaging/Staining
-
In Vivo Imaging
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CuFi-1 | IC50 |
2 μM
Compound: 1; D-NBDNJ
|
Anti-inflammatory activity in human CuFi1 cells assessed as reduction in Pseudomonas aeruginosa PAO1-induced IL-8 mRNA expression level pretreated for 1 hr followed by Pseudomonas aeruginosa PAO1 challenge and measured after 4 hrs by RT-PCR analysis
Anti-inflammatory activity in human CuFi1 cells assessed as reduction in Pseudomonas aeruginosa PAO1-induced IL-8 mRNA expression level pretreated for 1 hr followed by Pseudomonas aeruginosa PAO1 challenge and measured after 4 hrs by RT-PCR analysis
|
[PMID: 31075609] |
| MOLT-4 | CC50 |
>100 mg/mL
Compound: 3
|
Concentration giving 50% inhibition of growth of mock-infected MOLT-4 cells
Concentration giving 50% inhibition of growth of mock-infected MOLT-4 cells
|
[PMID: 7608901] |
| MOLT-4 | EC50 |
37 mg/mL
Compound: 3
|
Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MOLT-4 cells
Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MOLT-4 cells
|
[PMID: 7608901] |
| MT4 | CC50 |
>100 mg/mL
Compound: 3
|
Concentration giving 50% inhibition of growth of mock-infected MT-4 cells
Concentration giving 50% inhibition of growth of mock-infected MT-4 cells
|
[PMID: 7608901] |
| MT4 | EC50 |
49 mg/mL
Compound: 3
|
Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MT-4 cells
Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MT-4 cells
|
[PMID: 7608901] |
| RAW | IC50 |
50 μM
Compound: 1
|
Inhibition of glucosylceramide synthase in mouse RAW cells preincubated with compound for 15 mins by in-situ enzyme inhibition assay
Inhibition of glucosylceramide synthase in mouse RAW cells preincubated with compound for 15 mins by in-situ enzyme inhibition assay
|
[PMID: 24900289] |
| RAW | IC50 |
50 μM
Compound: 1, Zavesca
|
Inhibition of glucosylceramide synthase in mouse RAW cells preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence scanner
Inhibition of glucosylceramide synthase in mouse RAW cells preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence scanner
|
[PMID: 24900342] |
| SH-SY5Y | IC50 |
0.014 μM
Compound: 1; D-NBDNJ
|
Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay
Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay
|
[PMID: 31075609] |
| SH-SY5Y | IC50 |
118 μM
Compound: 1; D-NBDNJ
|
Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay
Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay
|
[PMID: 31075609] |
Miglustat (200 μM; 2, 4 and 24 h) restores F508del-CFTR (cystic fibrosis transmembrane conductance regulator) function in cystic fibrosis (CF) bronchial epithelial IB3-1 and CuFi-1 cells. Miglustat reduces the inflammatory response to P. aeruginosa in both CF and non-CF bronchial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NPC1−/− mice[1]
-
Dosage:0.2 mg/kg
-
Administration:Oral administration; once
-
Result:Was able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 72599-27-0
-
Appearance Solid
-
Peso molecular 219.28
-
Fòrmula C10H21NO4
-
Color White to off-white
-
SMILES
O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O
-
Synonyms
N-Butyldeoxynojirimycin; NB-DNJ; OGT 918
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Cell
2019 Dec 12;179(7):1483-1498.e22. PMID: 31813625 -
Nat Commun
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial. [Abstract]2024 Aug 14;15(1):6970. PMID: 39138212
Miglustat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 14;15(1):6970. [Abstract]
Miglustat combined with anti-PD-1 promotes tumour inhibition. MC38-OVA cells (1 × 105 328 ) were subcutaneously injected into C57BL/6 mice treated with PBS, Miglustat alone (10 mg/kg), anti-PD-1 antibody alone (200 mg/kg per mouse) or Miglustat plus anti-PD-1 as indicated and tumour formation was observed. Tumour sizes were measured every 3 days. The average and individual tumour curves are shown.
-
Cell Rep
The perinuclear theca protein Calicin helps shape the sperm head and maintain the nuclear structure in mice. [Abstract]2022 Jul 5;40(1):111049. PMID: 35793634
Miglustat purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks. NB-DNJ is a drug to disrupt the fusion of the small proacrosomal vesicles into a single acrosome. PNA-FITC-labeled acrosome and EGFP signals were almost lost after NB-DNJ treatment.
Miglustat purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks, the shape of sperm from Ccin-eGFP-KI mice was obviously changed and the acrosome was absent.
Miglustat purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]
Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks, The protein levels of Zpbp1 (an acrosomal marker) and eGFP-tagged calicin were significantly reduced.
-
Front Pharmacol
HECT, UBA and WWE domain containing 1 represses cholesterol efflux during CD4+ T cell activation in Sjögren's syndrome. [Abstract]2023 Jun 26:14:1191692. PMID: 37435494 -
J Virol
Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. [Abstract]2026 Apr 21;100(4):e0027026. PMID: 41910405 -
J Virol
STT3B promotes porcine epidemic diarrhea virus replication by regulating N-glycosylation of PEDV S protein. [Abstract]2025 Mar 18;99(3):e0001825. PMID: 39945486
Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Miglustat (5, 10 μM; 24 h) showed no cytotoxicity for Vero cells.
Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Miglustat (5, 10 μM) decreased the PEDV N mRNA levels in a dose-dependent manner in Vero cells.
Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Miglustat (5, 10 μM) decreased the PEDV N prodein levels in a dose-dependent manner in Vero cells.
Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]
Immunofluorescence assay (IFA) images of Vero cells infected with PEDV and treated with indicated Miglustat (5, 10 μM). Viral N-protein is shown in green, and the nuclei are blue.
-
Solvente y solubilidad
H2O : 175 mg/mL (798.07 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7(6):555-65. [Content Brief]
[2]. G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.5604 mL | 22.8019 mL | 45.6038 mL | 114.0095 mL |
| 5 mM | 0.9121 mL | 4.5604 mL | 9.1208 mL | 22.8019 mL | |
| 10 mM | 0.4560 mL | 2.2802 mL | 4.5604 mL | 11.4009 mL | |
| 15 mM | 0.3040 mL | 1.5201 mL | 3.0403 mL | 7.6006 mL | |
| 20 mM | 0.2280 mL | 1.1401 mL | 2.2802 mL | 5.7005 mL | |
| 25 mM | 0.1824 mL | 0.9121 mL | 1.8242 mL | 4.5604 mL | |
| 30 mM | 0.1520 mL | 0.7601 mL | 1.5201 mL | 3.8003 mL | |
| 40 mM | 0.1140 mL | 0.5700 mL | 1.1401 mL | 2.8502 mL | |
| 50 mM | 0.0912 mL | 0.4560 mL | 0.9121 mL | 2.2802 mL | |
| 60 mM | 0.0760 mL | 0.3800 mL | 0.7601 mL | 1.9002 mL | |
| 80 mM | 0.0570 mL | 0.2850 mL | 0.5700 mL | 1.4251 mL | |
| 100 mM | 0.0456 mL | 0.2280 mL | 0.4560 mL | 1.1401 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Miglustat Related Classifications
HY-17020 Related Classifications
Powered by Bioz